Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Gitlab Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Gitlab Inc trades at $33.15 (market cap $5.57B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| BIO | GTLB | |
|---|---|---|
Market Cap | $8.04B | $5.57B |
Sector | Health | Technology |
52-Week High | $339.75 | $51.04 |
52-Week Low | $241.71 | $19.42 |
Enterprise Value | $7.85B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GitLab (GTLB) trades at $33.47, up 3.24% today, with a bullish technical signal from moving averages and a consensus analyst price target of $31.93. The company reported strong revenue growth to $759.25 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven platform expansions, including a collaboration with Google Cloud.
The outlook is mixed; robust revenue growth and strategic positioning in AI and DevSecOps offer upside, but profitability challenges and high valuation multiples pose risks. Analyst sentiment is cautious with a majority hold rating, reflecting concerns over near-term execution versus long-term potential in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
